Hey all, was wondering if anyone listened to this talk with Rick Doblin published yesterday. He gets into the FDA disapproval of Lykos. What I’m confused about is his relation to Lykos- how is it different from MAPS? Were they not birthed from the same company & Doblin himself?

In this he claims that Lykos stopped him from responding to critics after FDA pushback. Definetly understand the criticism around this guy & the Lykos trials, but his thoughts on for-profits and media response in this shocked me.

Any thoughts ?

Hello! I am an undergraduate psychology student researcher at the University of Central Arkansas, and I am conducting a study on motivations for and outcomes of habitual use of psychedelics for my Honors College capstone project. It has been approved by the university’s institutional research board.

I would love to get a variety of survey responses, and I want to hear from you! This survey is fully anonymous, so it will not collect any personally identifying information or location data. I plan to have it open until December 1, 2024.

You are eligible to contribute if you are 18 years old or older, and use psychedelics of some variety more than once per year.

Here's the link: https://ucachbs.co1.qualtrics.com/jfe/form/SV_bPgi82qVNt0K6r4

I appreciate your help!

-Loren

If you have questions or comments, you can direct them to Lcruse[at]cub.uca.edu, or send me a direct message.